ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2017) 49 GP151 | DOI: 10.1530/endoabs.49.GP151

Growth hormone-releasing hormone (GHRH) antagonists, MIA-602 and MIA-690, inhibit survival and proliferation of human pleural mesothelioma cells

Tania Villanova1, Iacopo Gesmundo1, Marina Taliano1, Ezio Ghigo1, Andrew V Schally2,3 & Riccarda Granata1

1Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Torino, Torino, Italy; 2Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, Miami, Florida, USA; 3Department of Pathology and Department of Medicine, Divisions of Hematology, Oncology and Endocrinology, University of Miami Miller School of Medicine, Miami, Florida, USA.

Human malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm, arising from pleural mesothelial cells, generally due to asbestos exposure. Different growth factors are involved in the pathogenesis of MPM and in resistance to therapy; moreover, chemotherapy with cisplatin and antifolates, like pemetrexed (PEM), is the first-line treatment for inoperable MPM. Growth hormone-releasing hormone (GHRH), apart from stimulating GH secretion in the pituitary, exerts many extrapituitary functions, including stimulation of cell proliferation and survival. GHRH and GHRH receptor (GHRH-R) are expressed in different cancer cell types, where they modulate their proliferative effects. Moreover, GHRH-R antagonists were found to inhibit the proliferation of different cancer cells in vitro and in vivo; however, the role of GHRH antagonists in MPM remains unknown. Thus, in the present study, we investigated the effects of the GHRH antagonists MIA-602 and MIA-690 on survival, proliferation and apoptosis of human MPM cells. Our results show that MIA-602 and MIA-690 reduce survival and proliferation of MSTO-211H (biphasic) and REN (epithelioid) MPM cells, but have no effect in MeT-5A (human non-malignant mesothelial cells). Moreover, MIA-602 and MIA-690 promoted apoptosis and reduced the expression of the antiapoptotic protein Bcl-2 in MSTO-211H and REN cells. Cell cycle analysis of REN cells treated with GHRH antagonists showed an increase in the Sub-G1 apoptotic phase and a decrease in the G2 pre-mitotic phase. Furthermore, MIA-602 and MIA-690 inhibited cell migration in REN cells and increased the cytotoxic action of PEM in both MPM cell lines. These results suggest a novel therapeutic role for GHRH antagonists in the treatment of MPM, alone or in combination with standard therapies, by reducing the chemotherapy doses and their associated side effects.

Article tools

My recent searches

No recent searches.